

Brief Overview of the IOM committee on the Review of Clinical Guidance for the Care of Health Conditions Identified by the Camp Lejeune Legislation


**Responding to Communities:
Communicating the Science of TCE and PCE**
October 20, 2015

Patricia Janulewicz Lloyd, D.Sc., M.P.H.
Boston University School of Public Health



Review of VA Clinical Guidance for the Health Conditions Identified by the Camp Lejeune Legislation

www.iom.edu/lejeune



Suggested citation: IOM (Institute of Medicine). 2015. *Review of VA clinical guidance for the health conditions identified by the Camp Lejeune legislation*. Washington, DC: The National Academies Press.

INSTITUTE OF MEDICINE
OF THE NATIONAL ACADEMIES

IOM Committee members

- David R. Nerenz, Ph.D., Committee Chair
- Robert J. Alpern, M.D.
- Paolo Boffetta, M.D., M.P.H.
- Mary E. Davis, Ph.D.
- Michael E. Goldberg, M.D.
- Paul Grundy, M.D., M.P.H., FACOEM, FACPM
- Nancy L. Keating, M.D., M.P.H.
- Patricia A. Janulewicz Lloyd, D.Sc., M.P.H.
- Gary O. Rankin, Ph.D.
- Mark J. Utell, M.D.
- Carol S. Wood, Ph.D.
- Albert W. Wu, M.D., M.P.H.

Camp Lejeune




Figure 1. Location of U.S. Marine Corps Base, Camp Lejeune, North Carolina.

Janey Ensminger Act, 2012

- Honoring America's Veterans and Caring for Camp Lejeune Families Act
 - What it provides
 - Eligibility
 - VA clinical guidance
 - 15 health conditions
 - Esophageal cancer
 - Lung cancer
 - Breast cancer
 - Bladder cancer
 - Kidney cancer
 - Leukemia
 - Multiple myeloma
 - Myelodysplastic syndromes
 - Renal toxicity
 - Hepatic steatosis
 - Female infertility
 - Miscarriage
 - Scleroderma
 - Neurobehavioral effects
 - Non-Hodgkin's lymphoma

Committee's Task

- General Improvements
- Two specific tasks
 - Based on the latest scientific literature and the committee's review, describe the medical conditions that result from “renal toxicity” due to solvent exposure.
 - Based on the latest scientific literature and the committee's review, characterize the “neurobehavioral effects” as mandated for coverage in the law.

What is a Neurobehavioral
Effect??

The Committee's Decisions

- Exposure time period is a vital determinant
 - Prenatal and early Childhood exposure
 - Neurological symptoms resulting from neural tube defects
 - Adolescent and adult illicit drug use
 - Bipolar disorder

The Committee's Decisions

- Adult Exposure
 - Parkinson's disease
 - Symptoms or deficits in
 - Reaction time (delayed)
 - Problems with memory
 - Visuomotor function
 - Attention
 - Motor function
 - Contrast sensitivity
 - Color discrimination

Acknowledgements

IOM Committee Members

Roberta Wedge, Study director

Cary Haver, Associate Program Officer

Heather Chiarello, Research Associate

Roberta White, Ph.D.

Ann Aschengrau, Ph.D.


BU Superfund Program

Contact Information

Patricia Janulewicz Lloyd

paj@bu.edu

617-638-4778






FIGURE 3-2 Algorithm B-1—Neurobehavioral outcomes in adults exposed in utero or in early childhood.

ANNOTATIONS FOR ALGORITHM B-1:

B1—Identified neurobehavioral symptoms include illicit drug use, bipolar disorder, and neurological problems associated with neural tube defects, although not all committee members were in agreement on the inclusion of illicit drug use and bipolar disorder.

B2—Applicant does not have neurobehavioral symptoms as a covered condition and is not accepted to the Camp Lejeune program at this time.

B3—Applicant accepted into the Camp Lejeune program.




FIGURE 3-1 Algorithm B—Neurobehavioral outcomes.